BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 394890)

  • 1. In vivo anti-nuclear antibodies in epithelial biopsies in SLE and other connective tissue diseases.
    Wells JV; Webb J; Van Deventer M; Fry B; Pollard KM; Raftos J; Monk W; Nelson DS
    Clin Exp Immunol; 1979 Dec; 38(3):424-35. PubMed ID: 394890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal nuclear immunoglobulin deposition in connective tissue diseases.
    Rodrigues CJ; de Oliveira RM; Taniwaki NN; Bueno C; Marchiori P; Cossermelli W
    Rev Hosp Clin Fac Med Sao Paulo; 1990; 45(4):154-7. PubMed ID: 2135825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo antinuclear antibodies (ANA) in biopsies of normal skin: diagnostic significance and relation to serum ANA.
    Kallenberg CG; de Jong MC; Walstra TM; Kardaun S; The TH
    J Rheumatol; 1983 Oct; 10(5):733-40. PubMed ID: 6606041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear deposits of immunoglobulins in skin of patients with systemic lupus erythematosus.
    Shu S; Provost T; Croxdale MB; Reichlin M; Beutner EH
    Clin Exp Immunol; 1977 Feb; 27(2):238-44. PubMed ID: 300310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Sharp's syndrome. Clinical, immunological and nosographic aspects].
    Scagliusi P; Muratore M; Martiradonna A; Berlingerio G; Carrozzo M
    Minerva Med; 1980 Dec; 71(50):3655-63. PubMed ID: 6161325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody to extractable nuclear antigen in the rheumatic diseases.
    McCain GA; Bell DA; Chodirker WB; Komar RR
    J Rheumatol; 1978; 5(4):399-406. PubMed ID: 310883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological evaluation of in vivo epidermal nuclear fluorescence.
    Sousa JX; Miyamoto D; Zimbres JM; Costa DV; Aoki V
    Clin Exp Dermatol; 2009 Apr; 34(3):314-8. PubMed ID: 19040522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of three anti-double stranded DNA antibody assays on sera from SLE and other diseases.
    Clarke MC; Carr R; Burdash NM; Chen ZY; Ainsworth SK
    Diagn Immunol; 1986; 4(6):288-93. PubMed ID: 3545632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical significance of the in vivo antinuclear antibody phenomenon.
    Williams WV; Barjenbrach P; Adelstein E; Sharp GC; Walker SE
    Arch Pathol Lab Med; 1986 Sep; 110(9):798-802. PubMed ID: 3530186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positive direct immunofluorescence and autoantibody profiles in psoriasis patients.
    Janjumratsang P; Phainupong D; Chanjanakijskul S; Roongphibulsopit P
    J Dermatol; 2008 Aug; 35(8):508-13. PubMed ID: 18789071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-chromatin and anti-C1q antibodies in systemic lupus erythematosus compared to other systemic autoimmune diseases.
    Braun A; Sis J; Max R; Mueller K; Fiehn C; Zeier M; Andrassy K
    Scand J Rheumatol; 2007; 36(4):291-8. PubMed ID: 17763207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between the levels of antinuclear antibodies, anti-DNA antibodies, and complement in systemic lupus erythematosus.
    Nguyen CP; Cao VV; Fehér J; Gergely P
    Acta Med Hung; 1988; 45(2):145-59. PubMed ID: 3266790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunochemical characteristics of antibodies to DNA in patients with active systemic lupus erythematosus.
    Ballou SP; Kushner I
    Clin Exp Immunol; 1979 Jul; 37(1):58-67. PubMed ID: 385188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and serological heterogeneity in patients with anticentromere antibodies.
    Miyawaki S; Asanuma H; Nishiyama S; Yoshinaga Y
    J Rheumatol; 2005 Aug; 32(8):1488-94. PubMed ID: 16078324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical significance of antinuclear antibodies in connective tissue disease.
    Pahor A; Krajnc I; Gorenjak M; Holc I
    Wien Klin Wochenschr; 1998 May; 110(9):338-41. PubMed ID: 9629626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-telomere antibodies in systemic lupus erythematosus (SLE): a comparison with five antinuclear antibody assays in 430 patients with SLE and other rheumatic diseases.
    Salonen EM; Miettinen A; Walle TK; Koskenmies S; Kere J; Julkunen H
    Ann Rheum Dis; 2004 Oct; 63(10):1250-4. PubMed ID: 15361381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serial estimation of anti-RNP antibody titers in systemic lupus erythematosus, mixed connective tissue disease and rheumatoid arthritis.
    Nishikai M; Okano Y; Mukohda Y; Sato A; Ito M
    J Clin Lab Immunol; 1984 Jan; 13(1):15-9. PubMed ID: 6609234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The autoantibody profile and disease activity in patients with systemic lupus erythematosus].
    Horák P; Hermanová Z; Faltýnek L; Pospísil Z; Scudla V
    Vnitr Lek; 1997 Oct; 43(10):639-44. PubMed ID: 9601876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late onset systemic lupus erythematosus and lupus-like disease in patients with apparent idiopathic glomerulonephritis.
    Adu D; Williams DG; Taube D; Vilches AR; Turner DR; Cameron JS; Ogg CS
    Q J Med; 1983; 52(208):471-87. PubMed ID: 6606818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha-actinin-binding antibodies in relation to systemic lupus erythematosus and lupus nephritis.
    Becker-Merok A; Kalaaji M; Haugbro K; Nikolaisen C; Nilsen K; Rekvig OP; Nossent JC
    Arthritis Res Ther; 2006; 8(6):R162. PubMed ID: 17062137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.